Back to overview
Reuven Agami group
Group leader, Head of Division
Reuven Agami performed his PhD research (Thesis: Cell cycle and
apoptosis control induced by the tyrosine kinase c-Abl) within the
department of molecular genetics at the Weizmann Institute of
Science, Israel. During his research he identified a novel
DNA-damage-induced apoptosis pathway. As a post-doc in the group of
Rene Bernards he investigated rapid molecular events that initiate
a p53 independent DNA damage response. In September 2001 he started
his own group at the Netherlands Cancer Institute, which consists
now of a senior postdoc, six postdocs, three PhD students and two
technician. His group developed first an RNAi vector system
(pSUPER) to stably knockdown genes in mammalian cells, and then
used it to identify novel human tumor suppressor genes.
Subsequently, his group developed a microRNA expression vector and
library and used it to identify oncogenic miRNAs.
Currently, the Agami team is studying the role of non-protein
coding RNAs and protein translation in cancer metastasis, cellular
response to cancer therapy, and acquired resistance. The team
characterizes novel RNA functions, and tests their impact on cancer
progression. Their goal is to drive lab discoveries to the benefit
of cancer diagnosis and therapy.